Although limited evidence exists in adolescents, the combination of the two therapeutics (i.e., GLP-1 receptor agonists and high-intensity exercise) may further enhance obesity-related outcomes [31], with exercise playing a key role in maintaining weight loss after the discontinuation of pharmacological treatment [32], as it has been suggested in adults. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.